Toxicity in patients receiving adjuvant docetaxel plus hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer : a preplanned safety report of the SPCG-13 trial

P.-L. Kellokumpu-Lehtinen,Marie Hjälm-Eriksson,Camilla Thellenberg Karlsson,L. Åström,Lars Franzén,Timo Marttila,Mihalj Seke,M. Taalikka,Claes Ginman

Toxicity in patients receiving adjuvant docetaxel plus hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer : a preplanned safety report of the SPCG-13 trial

2012

P.-L. Kellokumpu-Lehtinen
Marie Hjälm-Eriksson
Camilla Thellenberg Karlsson
L. Åström
Lars Franzén
Timo Marttila
Mihalj Seke
M. Taalikka
Claes Ginman

BACKGROUND: Radical radiotherapy (RD combined with androgen deprivation therapy is currently the standard treatment for elderly patients with localized intermediate- or high-risk prostate cancer (P ...

Keywords:

Benign prostatic hyperplasia (BPH)
Urology
Cancer
Prostatectomy
Prostate cancer
Standard treatment
Radiation therapy
Androgen deprivation therapy
Medicine
Docetaxel
Oncology
Prostate-specific antigen
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations